Condition: Sarcoma · Radiosurgery · Sponsor: Centre Antoine Lacassagne
Up to 50% of soft tissue sarcoma (STS) patients will develop metastases in the course of their disease. Cytotoxic therapy is a standard treatment in this setting but yields average tumor response rates of 25% at first line and ≤10% at later lines. It is also limited in the number of lines and courses by tolerance issues. Trials include poly/oligometastases indistinctively and suggest that consolidation ablation is used in \~20% of patients with residual oligometastases refractory to chemotherapy. Oligometastases represent a stage of disease between completely absent and widely metastatic, and which might be cured if the limited numbers of metastatic sites are eradicated. Ablative strategies to treat patients with oligometastases from sarcomas yield prolonged survival times and stereotactic body radiation therapy (SBRT) is associated with excellent tolerance. Surgery may be offered in selected metastatic cases. Alternatively and increasingly, SBRT yields high control rates at treated sites (≥ 80%). The so-called radioresistance of sarcomas is overcome by the high doses per fraction made possible owing to the high precision achieved with SBRT. SBRT is an accepted treatment strategy provided that tumor burden remains limited in the number and size of metastases. Systemic treatment can be combined with SBRT. SBRT may produce abscopal effects where tumors outside the irradiation area also demonstrate tumor shrinkage in some occurrences. SBRT produces systemic antitumoral immune re…
This description comes directly from the study's public registry record.
Colin DEBAIGT, PhD · 0033 4 92 03 17 78 · DRCI-Promotion@nice.unicancer.fr
Always discuss trial participation with your own doctor first.
| Institut Bergonié | Bordeaux, France | Recruiting |
| Centre François BACLESSE | Caen, France | Not Yet Recruiting |
| Centre Georges François LECLERC | Dijon, France | Not Yet Recruiting |
| Centre Oscar LAMBRET | Lille, France | Not Yet Recruiting |
| Centre Léon BERARD | Lyon, France | Not Yet Recruiting |
| AP-HM CHU La Timone | Marseille, France | Active Not Recruiting |
| Institut Paoli CALMETTES | Marseille, France | Not Yet Recruiting |
| Institut de cancérologie de Montpellier | Montpellier, France | Recruiting |
| Centre Antoine LACASSAGNE | Nice, France | Recruiting |
| APHP La Pitié | Paris, France | Not Yet Recruiting |
| CHU de Poitiers | Poitiers, France | Active Not Recruiting |
| Centre Eugene MARQUIS | Rennes, France | Not Yet Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03548428